Filter

71 - 80 of 438 Results

  • Considerations for Covering Over-the-Counter Contraception

    Policy Watch

    In October 2023, the Departments of the Treasury, Labor, and Health and Human Services issued a request for information to gather public input about the potential benefits, costs, and implementation considerations of requiring private health insurance plans to cover OTC preventive services and supplies without a prescription. This policy watch addresses key considerations for the implementation of insurance coverage for non-prescribed OTC contraceptives based on the lessons learned from KFF’s 2023 study of Insurance Coverage of OTC Oral Contraceptives.

  • Insurance Coverage of OTC Oral Contraceptives: Lessons from the Field

    Report

    This report is based on 35 structured interviews conducted from January to August 2023, with nearly 80 experts and key players such as pharmacists, health plans, and state Medicaid officials involved in the coverage and provision of OTC contraception in seven states with one or more of these coverage approaches (IL, NJ, NM, NY, OR, UT, and WA). It discusses the challenges and successes in coverage under private health insurance and Medicaid and reviews policy options for operationalizing insurance coverage of non-prescribed OTC contraception such as Opill.

  • LGBT+ People’s Health Status and Access to Care

    Issue Brief

    This report, based on a nationally representative 2022 KFF survey, provides an analysis of the health experiences of self-identified LGBT+ adults in the U.S. compared to their non-LGBT+ counterparts.

  • A National Survey of OBGYNs’ Experiences After Dobbs

    Report

    This report, based on a nationally representative survey of office-based OBGYNs practicing in the United States, examines the provision of sexual and reproductive health care provided by OBGYNs before and after the Dobbs decision, comparing the experiences of OBGYNs practicing in states where abortion is fully banned, states with gestational restrictions, and states where abortion remains available under most circumstances.

  • Rebuilding the Title X Network Under the Biden Administration

    Issue Brief

    This issue brief examines what has happened to the Title X network under the Biden Administration regulations, including the number of clinics that have returned to the network, new funding, and how state policies that prohibit pregnancy options counseling that includes abortion and referrals may impact grantees' participation in the Title X program.

  • Update on the Status of Medication Abortion and the Courts

    Policy Watch

    This policy watch explains the April 21, 2023 United States Supreme Court's ruling on Alliance for Hippocratic Medicine v. FDA, a case challening the FDA's approval of mifepristone, the medication abortion pill.